Non-alcoholic steatohepatitis: What can we learn from animal models?

Current Medicinal Chemistry

Volumn 19, Issue 9, 2012, Pages 1389-1404

  Almonacid Urrego, C C ^a,b   Sanchez Campos S ^a   Tunon M J ^a   Gonzalez Gallego J ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Colombia   (Colombia)

Author keywords

Animal models; atherogenesis; dietary models; genetic models; non alcoholic steatohepatitis

Indexed keywords

FRUCTOSE;

ATHEROGENIC DIET; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL MONKEY; EXPERIMENTAL MOUSE; EXPERIMENTAL PIG; EXPERIMENTAL RABBIT; FIBROSIS; GENETIC ANALYSIS; GENETIC MODEL; HUMAN; LIPID DIET; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL ETHICS; METHIONINE DEFICIENCY; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL STATUS; REVIEW; SUGAR INTAKE; VITAMIN DEFICIENCY;

ANIMALS; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; LIVER; MUTATION; PHARMACEUTICAL PREPARATIONS;

EID: 84858126932     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799462586     Document Type: Review

References (157)

1. Ludwig, J.; Viggiano, T.R.; McGill, D.B.; Oh, B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 1980, 55, 434-448.
2. Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: old questions and new insights. Science. 2011, 332. 1519-1523.
3. Shifflet, A.; Wu, G.Y. Non-alcoholic steatohepatitis: an overview. J. Formos. Med. Assoc., 2009, 108, 4-12.
4. Miquelina-Colina, M.E.; Lima, E.; Sanchez-Campos, S.; García-Mediavilla, M.V.; Fernández-Bermejo, M.; Lozano-Rodríguez, T.; Vargas-Castrillón, J.; Buqué, X.; Ochoa, B.; Aspichueta, P, González-Gallego J, García-Monzón C. Hepatic fatty acid traslocase CD36 overexpression is associated with insulin resistance and increased steatosis in NASH and chronic hepatitis C. Gut, 2011, 60, 1394-1402.
5. Portincasa, P.; Grattagliano, I.; Palmieri, V.; Palascino, G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin. Biochem., 2005, 38, 203-217.
6. Argo, C.K.; Northup, P.G.; Al-Osaimi, A.M.; Caldwell, S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol., 2009, 51, 371-379.
7. Lima-Cabello, E.; Garcia-Mediavilla, V.; Miquilena-Colina, M.E.; Vargas-Castrillón, J.; Lozano-Rodríguez, T.; Fernández- Bermejo, M.; Olcoz, J.L.; González-Gallego, J.; García- Monzón, C.; Sánchez-Campos, S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin. Sci., 2011, 120, 239-250.
8. Kotronen, A.; Yki-Järvinen, H. Fatty Liver. A novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 27-38.
9. Larter, C.; Yeh, M. Animal models of NASH: Getting both pathology and metabolic context right. J. Gastroenterol. Hepatol., 2008; 23, 1635-1648.
10. Schattenberg, J.M.; Galle, P.R. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig. Dis., 2010, 28, 247-254.
11. Anstee, Q.M.; Goldin, R.D. Mouse models in NAFLD and steatohepatitis research. Int. J. Exp. Pathol., 2006, 87, 1-16.
12. Hebbard, L.; George, J. Animal models of non alcoholic fatty liver disease. Nature Reviews Gastroenterol. Hepatol., 2011, 8, 34-44.
13. Yamazaki, Y.; Kakizaki, S.; Takizawa, D.; Ichikawa, T.; Sato, K.; Takagi, H.; Mori, M. Interstrain differences in susceptibility to non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol., 2008, 15, 127-130.
14. Leclercq, I.; Lebrun, V.; Stärkel, P.; Horsmans, Y. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARσ agonist pioglitazone. Lab. Invest., 2007, 87, 56-65. (Pubitemid 44973654)
15. Kirsch, R.; Clarkson, V.; Verdonk, R.; Marais, A.; Shephard, E.; Ryffel, B.; Hall, P. Rodent nutritional model of steatohepatitis: Effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J. Gastroenterol. Hepatol., 2006, 21, 174-182.
16. Fisher, C.D.; Lickteiga, A.J.; Augustine, L.M.; Oude Elferink, R.P.; Besselsen, D.G.; Erickson, R.P.; Cherrington, N.J. Experimental NAFLD results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol., 2009, 613, 119-127.
17. Gyamfi, M.; Damjanov, I.; French, S.; Wan, Y.J. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem. Pharmacol., 2008; 75, 981-995.
18. Nagasawa, T.; Yoichi, I.; Shigeru N.; Tamura, T.; Takahashi, T.; Maruyama, K.; Yamazaki, Y.; Kuroda, J.; Shibata, N. Effects of bezafibrate, PPAR panagonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol., 2006; 536, 182-191.
19. Leclercq. I.; Farrell, G.; Field, J.; Bell, D.; Gonzalez, F.; Robertson, G. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest., 2000, 105, 1067-1075. (Pubitemid 30217691)
20. Sundaresan. S.; Vijayagopal, P.; Mills, N.; Imrhan, V.; Prasad, Ch. A mouse model for nonalcoholic steatohepatitis. J. Nutr. Biochem., 2011, 22, 789-794.
21. Rinella, M.; Green, R. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol., 2004, 40, 47-51. (Pubitemid 38064712)
22. Collins, S.; Martin, T.L.; Surwit, R.S.; Robidoux, J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse; physiological and molecular characteristics. Physiol, Behav., 2002, 81, 243-248. (Pubitemid 38670090)
23. London, R.; George, J. Pathogenesis of NASH: Animal models. Clin. Liver Dis., 2007. 11. 55-74. (Pubitemid 46829974)
24. Jian-Gao, F.; Liang, Q. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int., 2009, 8, 233-240.
25. Ip, E.; Farrell, G.; Hall, P.; Robertson, E.; Leclerq, I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology, 2004, 39, 1286-1296.
26. Leclercq, I.A.; Farrell, G.C.; Sempoux, C.; De la Peña, A.; Hormans, Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 2004, 41, 926-934.
27. De la Peña, A.; Leclercq, I.; Field, J.; George, J.; Jones, B.; Farell, G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 2005, 129, 1663-1674. (Pubitemid 41597405)
28. Yu, J.; Ip, E.; De la Peña, A.; Hou, J.Y., Sesha, J.; Pera, N.; Hall, P.; Kirsch, R.; Leclercq, I.; Farrell, G. C. COX-2 induction in mice with experimental nutritional steatohepatitis role as pro-inflammatory mediator. Hepatology, 2006, 43, 826-836.
29. Baumgardner, J.N.; Shankar, K.; Hennings, L.; Badger, T.M.; Ronis, M.J. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am. J. Physiol. Gastrointest. Physiol., 2008, 294, G27.
30. Oz, H.S.; Im, H.J.; Chen, T.S.; de Villiers, W.J.; Mc-Clain. C-J. Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J. Biochem. Mol. Toxicol., 2006, 20, 39-47.
31. Vergnes, L.; Phan, J.; Strauss, M.; Tafuri, S.; Reue, K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J. Biol. Chem., 2003, 278, 42774-42784. (Pubitemid 37345887)
32. Subramanian, S.; Goodspeed, L.; Wang, S.; Sesha, J.; Pera, N.; Hall, P.; Kirsch, R.; Leclercq, I.; Farell, G. C. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res., 2011, 52, 1626-1635.
33. Wouters, K.; van Gorp, P.J.; Bieghs, V.; et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology, 2008, 48, 474-486.
34. Ando, H.; Takamura, T.; Matsuzawa-Nagata, N.; Shima, K.R.; Nakamura, S.; Kumazaki, M.; Kurita, S.; Misu, H.; Togawa, N.; Fukushima, T.; Fujimura, A.; Kaneko, S. The hepatic circadian clock is preserved in a lipid-induced mouse model of non-alcoholic steatohepatitis. Biochem. Biophys. Res. Commun., 2009, 380, 684-688.
35. Basciano, H.; Miller, A.; Naples, M.; Baker, C.H.; Kohen, R. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab., 2009, 297, E462-E473.
36. Ahn, J.; Cho, I.; Kim, S.; Kwon, D.; Ha, T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J. Hepatol., 2008, 49, 1019-1028.
37. Matsuzawa, N.; Takamura, T.; Kurita, S.; Misu, H.; Ota, T.; Ando, H.; Yokoyama, M.; Honda, M.; Zen, Y.; Nakanuma, Y.; Miyamoto, K.; Kaneko, S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology, 2007, 46, 1392-1403. (Pubitemid 350155521)
38. Romestaing, C.; Piquet, M.A.; Bedu, E.; Rouleau, V.; Dautresme, M.; Hourmand-Olivier, I.; Flippi, C.; Duchamp, C.; Sibille, B. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr. Metab., 2007; 21, 1-4.
39. Lieber, C.S.; Leo, M.A.; Mak, K.M.; Xu, Y.; Cao, Q.; Ren, C.; Ponomarenko, A.; DeCarli, L. Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr., 2004, 79, 502-509. (Pubitemid 41115597)
40. Wang, Y.; Ausman, L.M.; Russell, R.M.; Greenberg, A.S.; Wang, X.D. Increased apoptosis in high-fat diet induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J. Nutr., 2008, 138, 176-181.
41. Ahmed, U.; Redgrave, T.; Oates, P. Effect of dietary fat to produce non-alcoholic fatty liver in the rat. Hepatology, 2009, 24, 1463-1471.
42. Wang, Y.; Seitz, H.; Wang, X. Moderate alcohol aggravates high-fat diet induced steatohepatitis in rats. Alcohol Clin. Exp. Res., 2010, 1, 567-573.
43. Gao, Y., Song, L.X., Jiang, M.N., Ge, G.Y., Jia, Y.J. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation, 2008, 31, 121-131.
44. Ji, G.; Zhao, X.; Leng, L.; Liu, P.; Jiang, Z. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis., 2011, 10, 23-33.
45. Gonzalez-Gallego, J.; Garcia-Mediavilla, M.V.; Sanchez-Campos, S. Hepatitis C virus, oxidative stress and steatosis: current status and perspectives. Curr. Mol. Med., 2011, 11, 373-390.
46. Ito, M.; Suzuki, J.; Tsujioka, S.; Sasaki, M.; Gomori, A.; Shirakura, T.; Hirose, H.; Ito, M.; Ishihara, A.; Iwaasa, H.; Kanatani, A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol. Res., 2007, 37, 50-57. (Pubitemid 46403840)
47. Li, Z.; Soloski, M.J.; Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology, 2005, 42, 880-885. (Pubitemid 41401126)
48. Deng, Q.G.; She, H.; Cheng, J.H.; French, S.W.; Koop, D.R.; Xiong, S.; Tsukamoto, H. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology, 2005, 42, 905-914. (Pubitemid 41401129)
49. Gaemers, I.; Stallen, J.M.; Kunne, C.; et al. Lipotoxicity and steatohepatitis in an overfed mouse model for NAFLD. Biochim Biophys Acta, 2011, 1812, 447-458.
50. Ogasawara, M.; Hirose, A.; Ono, M.; Aritake, K.; Nozaki, Y. A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet. Liver Intern., 2011, 31, 542-551.
51. Cong, W.N.; Tao, R.Y.; Tian, J.Y.; Liu, G.T.; Ye, F. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci., 2008, 82, 983-990.
52. Cettour-Rose, P.; Theander-Carrillo, C.; Asensio, C.; Klein, M.; Visser, T.J.; Burger, A.G.; Meier, C.A.; Rohner-Jeanrenaud, F. Hypothyroidism in rats decreases peripheral glucose utilization, a defect partially corrected by central leptin infusion. Diabetologia, 2005, 48, 621-623.
53. Zhao, J.; Zhou, G.; Li, M.; Li, W.; Lu, J.; Xiong, L.; Liang; L.; Zhao, Y.; Xu, D.; Yu, J. A novel non-alcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis. Scand. J. Gastroenterol., 2010, 45, 1360-1371.
54. Anania, F. NAFLD and fructose: Bad for us, better for mice. J. Hepatol., 2011, 55, 218-220.
55. Lim, J.S.; Mietus-Snyder, M.; Valente, A.; Schwarz, J.M.; Lustig, R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol., 2010, 7, 251-264.
56. Kanuri, G.; Spruss, A.; Wagnerberger, S.; Bischoff, S.C.; Bergheim, I. Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells. Lab. Invest., 2011, 91, 885-895.
57. Spruss, A.; Kanuri, G.; Wagnerberger, S.; Haub, S.; Bischoff, S.; Bergheim, I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology, 2009, 50, 1094-1104.
58. Huang, D.; Dhawan, T.; Young, S.; Yong, W.H., Boros, L.G.; Heaney, A.P. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis. 2011, 24, 10-20.
59. Bergheim, I.; Weber, S.; Vos, M.; Kramer, S.; Volvnets, V.; Kasserouni, S.; McClain, C.J.; Bischoff, S.C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol., 2008, 48, 983-992.
60. Botezelli, J.D.; Mora, R.F.; Dalia, R.A.; MNoura, L.P.; Cambri, L.T.; Ghezzi, A.C.; Voltarelli, F.A.; Mello, M.A. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis., 2010, 9, 116-124.
61. Nakagawa, T.; Hu, H.; Zharikov, S.; Tuttle, K.R.; Short, R.A.; Glushakova, O.; Ouyang, X.; Feig, D.I.; Block, E.R.; Herrera-Acosta, J.; Patel, J.M.;, Johnson, R.J. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol., 2006, 290, F625-F631.
62. Sánchez-Lozada, L.; Roncal, C.; Sautin, Y.; Sautin, Y.Y.; Abdelmalek, M.; Reunquiu, S.; Le, M.; Nakagawa, T.; Lan, H.Y.; Yu, X.; Johnson, R.J. Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur. J. Nutr., 2010, 49, 1-9.
63. Dillard, A.; Matthan, N.R.; Lichtenstein, A.H. Use of hamster as a model to study diet-induced atherosclerosis. Nutr. Metab., 2010, 7, 89-101.
64. Hamad, E.; Taha, S.; Abou, A.G.; et al. Protective effect of whey proteins against nonalcoholic fatty liver in rats. Lipids Health Dis., 2011, 10, 57.
65. Tetri, L.; Basaranoglu, M.; Brunt, E.; Yerian, L.; Neuschwander-Tetri, B. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 295, G987-G995.
66. Otogawa, K.; Kawada, N. Rabbit model for the study of human NASH. Nihon Rinsjo, 2006, 64, 1043-1047.
67. Otogawa, K.; Kinoshita, K.; Fujii, H.; Skabe, M.; Shiga, R.; Nakatani, K.; Shiga, M.; Shiga, R.; Nakatani, K.; Ikeda, K.; Nakajima, Y.; Ikura, Y.; Ueda, M.; Arakawa, T.; Hato, F.; Kawada, N. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am. J. Pathol., 2007, 170, 967-980. (Pubitemid 47339365)
68. Ogawa, T.; Fujii. H.; Yoshizato, K.; Kawada, N. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am. J. Pathol., 2010, 177, 153-165.
69. Sturzeneker, M.C.; Ioshii, S.O.; Villela Baroncini, L.A.; Précoma, D.B. Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis, 2011, 216, 97-102.
70. Fu, J.F.; Fang, Y.L.; Liang, L.; Wang, C.L.; Hong, F.; Dong, G.P. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J. Gastroenterol., 2009; 28; 15: 912-918.
71. Lee, L.; Alloosh, M.; Saxena, R.; Van Alstine, W.; Watkins, B.A.; Klaunig, J.E.; Sturek, M.; Chalasani, N. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology, 2009, 50, 56-67.
72. Bell, L.; Lee, L.; Saxena, R.; Bemis, K.G.; Wang, M.; Theodorakis, J.L.; Vuppalanchi, R.; Alloosh, M.; Sturek, M.; Chalasani, N. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am. J. Physiol. Gastrointest. Liver. Physiol., 2010, 298, G746-G754.
73. Fullenkamp, A.M.; Bell, L.N.; Robbins, R.D.; Lee, L.; Saxena, R.; Alooosh, M.; Klaunig, J.E.; Mirmira, R.G.; Sturek, M.; Chalasani, N. Effect of different obesogenic diets on pancreatic histology in Ossabaw miniature swine. Pancreas, 2011, 40, 438-443.
74. Kuwashiro, Sh.; Terai, Sh.; Oishi T.; Fujisawa, K.; Matsumoto, T.; Nishina, H.; Sakaida, I. Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. Cell Tissue Res., 2011, 344, 125-134.
75. Matsumoto, T.; Terai, Sh.; Oishi, T.; Kuwashiro, S.; Fujisawa, K.; Yamamoto, N.; Fujita, Y.; Hamamoto, Y.; Furutani-Seiki, M.; Nishina, H.; Sakaida, I. Medaka as a model for human nonalcoholic steatohepatitis. Dis. Models Mech., 2010, 3, 431-440.
76. Espe, M.; Rathore, R.M.; Du, Z.Y.; Liaset, B.; El-Mowafi, A. Methionine limitation results in increased hepatic FAS activity, higher liver 18:1 18:0 fatty acid ratio and hepatic TAG accumulation in Atlantic salmon, Salmo salar. Amino Acids, 2010, 39, 449-60.
77. Ayala, I.; Castillo, A.M.; Adánez, G.; Fernández-Rufete, A.; Pérez, B.G.; Castells, M.T. Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. Exp. Biol. Med., 2009, 234, 10-16.
78. Nagarajan, P.; Venkatesan, R.; Kumar, M,; Majumdar, S.S. Effects of ketamine and thiopentone anesthesia on serum lipid parametres in adult Bonnet monkeys (Macaca radiate). J. Am. Assoc. Lab. Anim. Sci., 2007, 46, 21-23. (Pubitemid 47068013)
79. Nagarajan, P.; Venkatesan, R.; Kumar, M.; Usmani, A.; Majumdar, S.S. Macaca radiata (bonnet monkey): a spontaneous model of nonalcoholic fatty liver disease. Liver Int., 2008, 28, 856-864. (Pubitemid 351818649)
80. Fan, J.G.; Qiao, L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat, Dis, Int., 2009, 8, 233-240.
81. Xu, Z.J.; Fan, Jg.; Ding, X.D.; Qiao, L.; Wang, G.L. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig. Dis. Sci., 2010, 55, 931-940.
82. Wanless, I.R.; Shiota, K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis., 2004, 24, 99-106. (Pubitemid 38496052)
83. Nanji, A.A. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin. Liver Dis., 2004, 8, 559-574. (Pubitemid 39141143)
84. Honda, H.; Ikejima, K.; Hirose, M.; Yoshikawa, M.; Lang, T.; Enomoto, N.; Kitamura, T.; Takei, Y.; Sato, N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology, 2002, 36, 12-21. (Pubitemid 34700757)
85. Leclercq, I.A.; Farrell, G.C.; Schriemer, R.; Robertson, R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol., 2002, 37, 206-213.
86. Haque, J.A.; McMahan, R.S.; Campbell, J.S.; Shimizu-Albergine, M.;, Wilson, A.M.; Botta, D.; Bammler, T.K.; Beyer, R.P.; Montine, T.J.; Yeh, M.M,; Kavanagh, T.J.; Fausto, N. Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab. Invest., 2010, 90, 1704-1717.
87. Lindström, P. The physiology of obese-hyperglycemic mice [ob/ob mice]. Scient. World J., 2007, 7, 666-685.
88. Gautron, L.; Elmquist, J.K. Sixteen years and counting: an update on leptin in energy balance. J. Clin. Invest., 2011, 121, 2087-2093.
89. Denechaud, P.D.; Dentin, R.; Girard, J.; Postic, C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett., 2008, 582, 68-73. (Pubitemid 350297238)
90. Koteish, A.; Diehl, A.M. Animal models of steatohepatitis. Best Practice Res. Clin. Gastroenterol., 2002, 16, 679-690.
91. Unger, R.H., Orci, L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J., 2001, 15, 312-321. (Pubitemid 32141423)
92. Varela-Rey, M.; Embade, N.; Ariz, U.; Lu, S.C.; Mato, J.M. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int. J. Biochem. Cell. Biol., 2009, 41, 969-976.
93. Yang, S.; Zhu, H.; Li, Y.; Lin, H.; Gabrielson, K.; Trush, M.A.; Diehl, A.M. Mitochondrial adaptations to obesity-related oxidant stress. Arch. Biochem. Biophys., 2000, 378, 259-268. (Pubitemid 30397626)
94. Yang, Z.H.; Miyahara, H.; Hatanaka, A. Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis., 2011, 10, 120-128.
95. Deveaux, V.; Cadoudal, T.; Ichigotani, Y.; Teixeira-Clerc, F.; Louvet, A.; Manin, S.; Nhieu, J.T.; Belot, M.P.; Zimmer, A.; Even, P.; Cani, P.D.; Knauf, C.; Burcelin, R.; Bertola, A.; Le Marchand-Brustel, Y.; Gual, P.; Mallat, A.; Lotersztajn, S. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. Plos One, 2009, 4, e5844.
96. Li, Z.; Yang, S.; Lin, H.; Huang, J.; Watkisn, P.A. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003, 37, 343-350.
97. El-Badry, A.M.; Moritz, W.; Contaldo, C.; Tian, Y.; Graf, R.; Clavien, P.A. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology, 2007, 45, 855-863.
98. Oliveira, C.P.; Alves, V.A.; Lima, V.M.; Stefano, J.T.; Debbas, V.; Sá, S.V.; Wakamatsu, A.; Corrêa-Giannella, M.L.; de Mello, E.S.;, Havaki, S.; Tiniakos, D.G.; Marinos, E.; de Oliveira, M.G.; Giannella-Neto, D.; Laurindo, F.R.; Caldwell, S.; Carrilho, F.J. Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice. Biochem. Pharmacol., 2007, 74, 290-297.
99. Stefano, J.T.; de Oliveira, C.P.; Corrêa-Giannella, M.L.; de Lina V.M.-; dde Sa, S.V.; de Oliveira, E.P., Mello, E.S.; Giannella-Neto, D.; Carrilho, F.J. Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig. Dis. Sci., 2007, 52. 3448-3454. (Pubitemid 350077199)
100. Abu-Shanab, R.; Quiqley, E.M. The role of the gut microbiota in non alcoholic faty liver disease. Gastroenterol. Hepatol., 2010, 7, 691-701.
101. Baker, S.S., Baker, R.D., Liu, W.; Nowak, N.J.; Zhu, L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLos One, 2010, 5, e9570.
102. Cope, K.; Risby, T.; Diehl, A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology, 2000, 119, 1340-12347.
103. Sahai, A.; Malladi, P.; Pan, X.; Paul, R.; Melin-Aldana, H. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287, G1035-G1043. (Pubitemid 39423696)
104. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology, 2007, 45, 1366-1374. (Pubitemid 46918320)
105. Wortham, M.; He, L.; Gyamfi, M.; Copple, B.L.; Wan, Y.J. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci., 2008, 53, 2761-2774.
106. Witek, R.P.; Stone, W.C.; Karaca, F.G.; Syn, W.K.; Pereira, T.A.; Agboola, K.M.; Omenetti. A.; Jung, Y.; Teaberry, V.; Choi, S.S.; Guy, C.D.; Pollard, J.; Charlton, P. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology, 2009, 50, 1421-1430.
107. Rinella, M.E.; Smolak, R.R.; Fu, T.; Gree, R.M. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res., 2008, 49, 1068-1076.
108. Yamaguchi, K.; Itoh, Y.; Yokomizo, C.; Nishimura, T.; Niimi, T. Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-fed db/db mice. Lab. Invest., 2011, 91, 609-618.
109. Diehl, A.M. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am. J. Physiol. Gastrointest. Liver Physiol., 2002; 282, G1-G5.
110. Carmiel-Haggai, M.; Cederbaum, A.I.; Nieto, N. A high-fat diet leads to the progression of NAFLD in obese rats. FASEB J., 2005, 19, 136-138. (Pubitemid 40069943)
111. Gómez-Zorita, S.; Fernández-Quintela, A.; Macarulla, M.T.; Aguirre, L.; Hijona, E.; Bujanda, L.; Milagro, F.; Martínez, J.A.; Portillo, M.P. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr., 2011, 28, 1-9.
112. Arsov, T.; Silva, D.G.; O'Bryan, M.K.; Sainsbury, A.; Lee, N.J.; Kennedy, C.; Manji, S.S.; Nelms, K.; Liu, C.; Vinuesa, C.G.; de Kretser, D.M.; Goodnow, C.C.; Petrovsky, N. Fat aussie-a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol. Endocrinol., 2006, 20, 1610-1622. (Pubitemid 43967568)
113. Purvis, T.L.; Hearn, T.; Spalluto, C.; Knorz, V.J.; Hanley, K.P.; Sanchez- Elsner, T.; Hanley, N.A.; Wilson, D.I. Transcriptional regulation of the Alström syndrome gene ALMS1 by members of the RFX family and Sp1. Gene, 2010, 15, 460, 20-29.
114. Arsov, T.; Larter, C.Z.; Nolan, C.J.; Petrovsky, N.; Goodnow, C.C.; Teoh, N.C.; Yeh, M.M.; Farrell, G.C. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem. Biophys. Res. Commun., 2006, 342, 1152-1159.
115. Atherton, H.J.; Gulston, M.K.; Bailey N.J.; Cheng, K.K.; Zhang, W.; Clarke, K.; Griffin, J.L. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Mol. Syst. Biol., 2009, 5, 259-269.
116. Leone, T.C.; Weinheimer, C.J.; Kelly, D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the cellular fasting response: the PPAR alpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA, 1999, 96, 7473-7478. (Pubitemid 29299686)
117. Ip, E.; Farrell, G.C.; Robertson, G.; Hall, P.; Kirsch, R.; Leclercq, I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology, 2003, 38, 123-132. (Pubitemid 36775803)
118. Guelzim, N.; Huneau, J.F.; Mathé, V.; Quignard-Boulangé, A.; Martin, P.G.; Tomé, D.; Hermier, D. Consequences of PPAR(α) invalidation on glutathione synthesis: Interactions with dietary fatty acids. PPAR Res., 2011, 2011, 256186.
119. Abdelmegeed, M.A.; Yoo, S.H.; Henderson, L.E.; Gonzalez, F.J.; Woodcroft, K.J.; Song, B.J. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr., 2011, 141, 603-610.
120. Ramdhan, D.H.; Kamijima, M.; Wang, D.; Ito, Y.; Naito, H.; Yanagiba, Y.; Hayashi, Y.; Tanaka, N.; Aoyama, T.; Gonzalez, F.J.; Nakajima, T. Differential response to trichloroethylene-induced hepatosteatosis in wildtype and PPARalpha-humanized mice. Environm. Healt Perspect., 2010, 118, 1557-1563.
121. Yu, S.; Matsusue, K.; Kasghireddy, P.; Cao, W.Q.; Yeldandi, V.; Rao, M.S.; Gonzalez, F.J.; Reddy, J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome prolifer-atoractivated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem, 2003, 278, 498-505. (Pubitemid 36043602)
122. Martinez-Jimenez, C.P., Kyrmizi, I., Cardot, P., Gonzalez, F.J., Talianidis, I. Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. Mol. Cell Biol., 2010, 30, 565-577.
123. Gonzalez, F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res., 2005, 569, 101-110. (Pubitemid 39643260)
124. Rountree, C.B.; Senadheera, S.; Mato, J.M.; Crooks, G.M.; Lu, S.C. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology, 2008, 47, 1288-1297. (Pubitemid 351547915)
125. Cook, W.S.; Jain, S.; Jia, Y.; Cao, W.Q.; Yeldandi, A.V.; Reddy, J.K.; Rao, M.S. Peroxisome proliferator-activated receptor alpha-responsive genes induced in the newborn but not prenatal liver of peroxisomal fatty acyl-CoA oxidase null mice. Exp. Cell Res., 2001, 268, 70-76. (Pubitemid 32678861)
126. Vluggens, A.; Andreoletti, P.; Viswakarma, N.; Jia, Y.; Matsumoto, K.; Kulik, W.; Khan, M.; Huang, J.; Guo, D.; Yu, S.; Sarkar, J.; Singh, I.; Rao, M.S.; Wanders, R.J.; Reddy, J.K.; Cherkaoui-Malki, M. Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform. Lab. Invest. 2010, 90, 696-708.
127. Ohtsuji, M.; Katsuoka, F.; Kobayashi, A.; Aburatani, H.; Hayes, J.D.; Yamamoto, M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J. Biol. Chem., 2008, 283, 33554-33562.
128. Xu, Z.; Chen, L.; Leung, L.; Yen, T.S.; Lee, C.; Chan, J.Y. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. USA, 2005, 102, 4120-4125. (Pubitemid 40388565)
129. Horie, Y.; Suzuki, A.; Kataoka, E.; Sasaki, T.; Hamada, K.; Sasaki, J.; Mizuno, K.; Hasegawa, G.; Kishimoto, H.; Iizuka, M.; Naito, M.; Enomoto, K.; Watanabe, S.; Mak, T.W.; Nakano, T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest., 2004, 113, 177417-17783.
130. Anezaki, Y.; Ohshima, S.; Ishii, H.; Kinoshita, N.; Dohmen, T.; Kataoka, E.; Sato, W.; Iizuka, M.; Goto, T.; Sasaki, J.; Sasaki, T.; Suzuki, A.; Ohnishi, H.; Horie, Y. Sex difference in the liver of hepatocyte-specific Pten-deficient mice: A model of nonalcoholic steatohepatitis. Hepatol. Res., 2009, 39, 609-618.
131. Lai, K.K.; Shang, S.; Lohia, N.; Booth, G.C.; Masse, D.J.; Fausto, N.; Campbell, J.S.; Beretta, L. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet., 2011, 7, e1002147.
132. Yan, H.; Shvy, J.Y.; Martins-Green, M. Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. J. Hepatol., 2009, 51, 535-547.
133. Nakayama, H.; Otabe, S.; Ueno, T.; Hirota, N.; Fukutani, T.; Wada, N.; Hashinaga, T.; Yamada, K. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism, 2007, 56, 470-475. (Pubitemid 46427843)
134. Tous, M.; Ferré, N.; Camps, J.; Riu, F.; Joven, J. Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol. Cell Biochem., 2005, 268, 53-58.
135. Tous, M.; Ferré, N.; Camps, J.; Joven, J. Efectos de la dieta hipercolesterolemiante en el animal de experimentación. Clin. Invest. Arterioscl., 2002, 14, 107.
136. Shiri-Sverdlov, R.; Wouters, K.; van Gorp, P.J.; Gijbels, M.J.; Noel, B.; Buffat, L.; Staels, B.; Maeda, N.; van Bilsen, M.; Hofker, M.H. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol., 2006, 44, 732-741.
137. Karavia, E.A.; Papachristou, D.J.; Kotsikogianni, I.; Giopanou, I.; Kypreos, K.E. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice. FEBS J., 2011, 278, 3119-3129.
138. Suto, J.; Sekikawa, K. Confirmation and characterization of murine body weight QTLs, Bwq1 and Bwq2, identified in C57BL/6J x KK-Ay/a F2-Ay/a mice. J. Vet. Med. Sci., 2004, 66, 1039-1045. (Pubitemid 41380203)
139. Yamada, K.; Hosokawa, M.; Yamada, C.; Watanabe, R.; Fujimoto, S.; Fujiwara, H.; Kunitomo, M.; Miura, T.; Kaneko, T.; Tsuda, K.; Seino, Y.; Inagaki, N. Dietary corosolic acid ameliorates obesity and hepatic steatosis in KK-Ay mice. Biol. Pharm. Bull., 2008, 31, 651-655. (Pubitemid 351500500)
140. Masaki, T.; Chiba, S.; Tatsukawa, H.; Yasuda, T.; Noguchi, H. Adiponectin protects LPS-Induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology, 2004, 40, 177-184. (Pubitemid 38868936)
141. Johansson, E.; Wesselkamper, S.C.; Shertzer, H.G.; Leikauf, G.D.; Dalton, T.P.; Chen, Y. Glutathione deficient C57BL/6J mice are not sensitized to ozone-induced lung injury. Biochem. Biophys. Res. Commun., 2010, 396, 407-412.
142. Iacobini, C.; Menini, S.; Fantauzzi, C.B.; Salvui, L.; Cordone, S.; Delucchi, F.; Serino, M.; Federici, M.; Pricci, F.; Pugliese, G. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J. Hepatol., 2011, 54, 975-983.
143. Luedde, T.; Beraza, N.; Kotsikoris, V.; van Loo, G.; Nenci, A.; De Vos, R.; Roskams, T.; Trautwein, C.; Pasparakis, M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell, 2007, 11, 119-132. (Pubitemid 46209851)
144. Wunderlich, F.T.; Luedde, T.; Singer, S.; Schmidt-Supprian, M.; Baumgartl, J.; Schirmacher, P.; Pasparakis, M.; Bruning, J.C. Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc. Natl. Acad. Sci. USA, 2008, 105, 1297-1302. (Pubitemid 351397047)
145. Kamada, Y.; Tamura, S.; Kiso, S.; Matsumoto, H.; Saji, Y.; Yoshida, Y.; Fukui, K.; Maeda, N.; Nishizawa, H.; Nagaretani, H.; Okamoto, Y.; Kihara, S.; Miyagawa, J.; Shinomura, Y.; Funahashi, T.; Matsuzawa, Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology, 2003, 125, 1796-1807. (Pubitemid 37500444)
146. Asano, T.; Watanabe, K.; Kubota, N.; Gunji, T.; Omata, M.; Kadowaki, T.; Ohnishi, S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J. Gastroenterol. Hepatol., 2009, 24, 1669-1676.
147. Mas, E.; Danjoux, M.; Garcia, V.; Carpentier, S.; Ségui, B.; Levade, T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One, 2009, 4, e7929.
148. Chen, Y.; Hozawa, S.; Sawamara, S.; Sato, S.; Fukuyama, N.; Tsuji, C.; Mine, T.; Okada, Y.; Tanin,o R.; Ogushi, Y.; Nakazawa, H. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem. Biophys. Res. Commun., 2005, 326, 45-51.
149. Grieco, A.; Forgione, A.; Miele, L.; Vero, V.; Greco, A.V.; Gasbarrini, A.; Gasbarrini, G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci., 2005, 9, 261-263. (Pubitemid 41387388)
150. Pessayre, D.; Fromenty, B.; Berson, A.; Robin. M.A.; Lettéron, P.; Moreau, R.; Mansouri, A. Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev., 2011; doi: 10.3109/03602532.2011.604086.
151. Berson, A.; De Beco, V.; Lettéron, P.; Robin, M.A.; Moreau, C.; El Kahwaji, J.; Verthier, N.; Feldmann, G.; Fromenty, B.; Pessayre, D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 1998, 114, 764-774. (Pubitemid 28160411)
152. Robin, M.A.; Descatoire, V.; Pessayre, D.; Berson, A. Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation. Toxicol. In Vitro., 2008, 22, 1511-1519.
153. Lettéron, P.; Sutton, A.; Mansouri, A.; Fromenty, B.; Pessayre, D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology, 2003, 38, 133-1340.
154. McCarthy, T.C.; Pollak, P.T.; Hanniman, E.A.; Sinal, C.J. Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. J. Pharmacol. Exp. Ther., 2004, 311, 864-873. (Pubitemid 39612690)
155. Cole, L.K.; Jacobs, R.L.; Vance, D.E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology, 2010, 52, 1258-1565.
156. Lee, M.H.; Kim, J.W.; Kim, J.H.; Kang, K.S.; Kong, G.; Lee, M.O. Gene expression profiling of murine hepatic steatosis induced by tamoxifen. Toxicol. Lett., 2010, 199, 416-424.
157. Chavez-Tapia, N.C.; Rosso, N.; Tiribelli, C. In vitro models for the study of non alcoholic fatty liver disease. Current Med. Chem., 2011, 18, 1079-1084.